Brand Names of Low-Dose Combined Oral Contraceptives
For a healthy, non-smoking woman of reproductive age, appropriate low-dose combined oral contraceptive pills containing 20-35 µg ethinyl estradiol with levonorgestrel or norethisterone include formulations such as those containing ethinyl estradiol 20-30 µg with levonorgestrel 100-150 µg, or ethinyl estradiol 20-35 µg with norethindrone acetate.
Levonorgestrel-Containing Formulations
The evidence strongly supports levonorgestrel-containing pills as having the lowest thrombotic risk profile among combined oral contraceptives. 1 Data show that pills with 20-30 µg ethinyl estradiol combined with levonorgestrel have comparable or lower venous thromboembolism risk compared to higher-dose formulations or those containing other progestins.
Available Formulations:
20 µg ethinyl estradiol + 100 µg levonorgestrel: This ultra-low-dose combination has demonstrated effective contraception with a Pearl Index of 0.88 and cumulative pregnancy rate of 1.9% over 3 years 2. Extended-cycle versions (84 active pills followed by 7 low-dose estrogen pills) are also available and reduce scheduled bleeding episodes to four per year 3, 4.
30 µg ethinyl estradiol + 150 µg levonorgestrel: This is the most commonly prescribed formulation, representing 84.4% of users in large studies 1. It serves as the reference standard for thrombotic risk assessment and has excellent efficacy and cycle control 5.
Norethindrone-Containing Formulations
Norethindrone acetate formulations provide an alternative with comparable safety:
20-30 µg ethinyl estradiol + 1.0-1.5 mg norethindrone acetate: Studies demonstrate these are effective and safe, with the 30 µg ethinyl estradiol/1.5 mg norethindrone acetate combination showing no differences in pregnancy rates or clinical acceptability compared to levonorgestrel formulations 6.
Ultra-low-dose option (10 µg ethinyl estradiol + 1.0 mg norethindrone acetate): This extended-cycle regimen (24 active days) reduces estrogen exposure by nearly half with a Pearl Index of 2.2, though it may have slightly higher breakthrough bleeding initially 7.
25 µg ethinyl estradiol + 0.8 mg norethindrone: Available as a chewable formulation in a 24/4 regimen with Pearl Index of 1.65-2.01 8.
Key Safety Considerations
Levonorgestrel-containing pills are preferred from a thrombotic risk perspective. 1, 9 The relative risk of venous thromboembolism with 30-35 µg ethinyl estradiol plus levonorgestrel serves as the baseline (OR = 1.0), while pills containing other progestins show 50-80% higher risk. 9
Important Caveats:
- All combined oral contraceptives increase VTE risk 3-9 per 10,000 woman-years compared to 1-5 per 10,000 in non-users 9
- Risk is highest in the first year of use 1
- Age >40 years, smoking, obesity, and thrombophilia significantly amplify risk 1
- The 20 µg ethinyl estradiol dose shows similar or lower thrombotic risk compared to 30 µg formulations with the same progestin 1
Practical Recommendations
Start with a monophasic pill containing 30 µg ethinyl estradiol with levonorgestrel or norgestimate as recommended by adolescent medicine experts 10. This provides optimal balance of efficacy, cycle control, and safety. If breakthrough bleeding occurs or lower estrogen exposure is desired, transition to 20 µg ethinyl estradiol formulations.
Extended-cycle regimens (84-91 days of active pills) reduce withdrawal bleeding episodes and may improve adherence, particularly beneficial for women desiring fewer menses 3, 4. These formulations include low-dose estrogen (10 µg) during the traditional placebo interval to reduce unscheduled bleeding.
Avoid non-oral routes (patches, vaginal rings) in this population as they increase thrombotic risk by a factor of 3-4 compared to oral formulations 1.
The choice between levonorgestrel and norethindrone formulations can be based on cost, insurance coverage, and individual tolerability, as both demonstrate comparable contraceptive efficacy in healthy women 10, 6. However, levonorgestrel maintains a slight advantage in thrombotic safety profile.